Loading…
GMAB
Genmab A/SNasdaqResearch view
Healthcare · Pharmaceutical Preparations · SEC EDGAR FY 2024-12-31
Price history
Interactive · live data via TradingView🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2024-12-31SectorHealthcare
Incomekr 7.8B
Saleskr 21.5B
Book/sh—
Cash/sh—
Dividend TTM—
Payout—
Employees—
IPO—
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
kr 10.1B
2020
kr 8.4B
2021
kr 14.5B
2022
kr 16.5B
2023
kr 21.5B
2024
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| DKK | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | kr 10.1B | kr 8.4B | kr 14.5B | kr 16.5B | kr 21.5B |
| Gross Profit | — | — | — | — | — |
| Operating Income | kr 6.3B | kr 3.0B | kr 6.3B | kr 5.3B | kr 6.7B |
| Net Income | kr 4.8B | kr 3.0B | kr 5.5B | kr 4.4B | kr 7.8B |
| Diluted EPS | kr 72.21 | kr 44.77 | kr 82.59 | kr 66.02 | kr 121.36 |
| Operating Cash Flow | kr 6.4B | kr 2.2B | kr 3.9B | kr 7.4B | kr 7.8B |
| Free Cash Flow | kr 6.1B | kr 2.0B | kr 3.6B | kr 7.0B | kr 7.6B |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
Follow the news. Follow the move.
GMAB story timeline
Company updates and connected market context, with the dated price move attached.
1
Stories
1
Direct
COMMUNITY · $GMAB0 theses
POST YOUR TAKE →Related Stocks
Loading peers…
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.